Miami Lakes, Florida Clinical Trials
A listing of Miami Lakes, Florida clinical trials actively recruiting patient volunteers.
Found 36 clinical trials
Open-Label Study With Pimavanserin on Activities of Daily Living in Subjects With Parkinson's Disease Psychosis
To assess the effect of pimavanserin on the activities of daily living in subjects with Parkinson's Disease Psychosis
- 0 views
- 19 Feb, 2024
- +18 other locations
A Study to Investigate the Pharmacokinetics and Safety of Dupilumab in Participants ≥6 Months to <18 Years of Age With Prurigo Nodularis
This is a Phase 3, multicenter, open-label, pharmacokinetics (PK)/safety study.The study consists of 3 periods:Screening period: 2 to 4 weeks.Treatment period: 24 weeks.Post-intervention follow-up period: 16 weeks. The study duration will be approximately 42 to 44 weeks for each participant (including screening, treatment, and follow-up periods).The total number of planned …
- 0 views
- 14 May, 2025
- +5 other locations
A Study Evaluating JUV DERM VOLUMA XC Injectable Gel for Correction of Temple Hollowing in Adult Participants Over 22 Years Old
The objectives of this study are to evaluate the safety and effectiveness of Juvederm Voluma XC injectable gel in adult participants seeking correction of temple hollowing
- 0 views
- 19 Feb, 2024
- +14 other locations
Study of a Pneumococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Toddlers and Infants
Primary Objective: To assess the safety profile of each SP0202 formulation and Prevnar 13 in toddlers and infants (after each and any injection). To assess the immune response (serotype specific IgG concentration) of the SP0202 formulations and Prevnar 13 1 month after the administration of one dose in toddlers (Groups …
- 0 views
- 19 Feb, 2024
- +31 other locations
Treatment of Moderate to Severe Lateral Canthal Lines and Glabellar Lines Alone or in Combination
This study is designed to evaluate the safety and efficacy of a single dose of QM1114-DP for the treatment of moderate to severe LCL and moderate to severe GL, alone or in combination.
- 0 views
- 19 Feb, 2024
- +9 other locations
PTI-125 100 mg for Mild-to-moderate Alzheimer's Disease Patients
An Open-label study for patients who completed the previous studies, PTI-125-02 or PTI-125-03. Additional new patients will be included for a total of 100 patients enrolled for this study.
- 0 views
- 19 Feb, 2024
- +8 other locations